Director Randy Thurman buys 5,000 Outlook Therapeutics (OTLK) shares in open market

Rhea-AI Filing Summary

Outlook Therapeutics director buys shares on the open market. Director Randy H. Thurman purchased 5,000 shares of Outlook Therapeutics common stock in an open-market transaction at $0.429 per share. Following this trade, he directly holds a total of 5,593 shares of the company.

Insider Trade Summary

Net Buyer: 5,000 shares ($2,145)

Net Buy 1 txn

Insider THURMAN RANDY H

Role null

Bought 5,000 shs ($2K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	5,000	$0.429	$2K

Holdings After Transaction: Common Stock — 5,593 shares (Direct, null)

Footnotes (1)

Key Figures

Shares purchased: 5,000 shares Purchase price: $0.429 per share Shares owned after transaction: 5,593 shares +1 more

4 metrics

Shares purchased 5,000 shares Open-market purchase of common stock

Purchase price $0.429 per share Price paid in the May 26, 2026 transaction

Shares owned after transaction 5,593 shares Director’s direct holdings following the trade

Net buy shares 5,000 shares Net-buy direction in transaction summary

Key Terms

open-market purchase, Common Stock, Form 4, net-buy

4 terms

open-market purchase financial

"transaction_action: open-market purchase"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

net-buy financial

"netBuySellDirection: net-buy"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

THURMAN RANDY H

(Last) (First) (Middle)

C/O OUTLOOK THERAPEUTICS, INC.

111 S. WOOD AVE, UNIT #100

(Street)

ISELIN NEW JERSEY 08830

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Outlook Therapeutics, Inc. [ OTLK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/26/2026		P		5,000	A	$0.429	5,593	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	Lawrence Kenyon, Attorney-in-Fact	05/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Outlook Therapeutics (OTLK) report for Randy H. Thurman?

Outlook Therapeutics reported that director Randy H. Thurman made an open-market purchase of 5,000 shares of the company’s common stock at $0.429 per share, as disclosed in a Form 4 insider trading report filed with regulators.

How many Outlook Therapeutics (OTLK) shares does Randy H. Thurman own after this trade?

After the reported purchase, Randy H. Thurman directly owns 5,593 shares of Outlook Therapeutics common stock. This total reflects his existing holdings plus the 5,000 shares acquired in the open-market transaction described in the Form 4 filing.

Was the Outlook Therapeutics (OTLK) insider trade an open-market purchase?

Yes, the transaction was an open-market purchase. The Form 4 classifies it with code P, indicating a purchase in the open market or a private transaction, with 5,000 common shares bought at a price of $0.429 per share.

Did the Outlook Therapeutics (OTLK) Form 4 show any insider sales?

No, the Form 4 for Outlook Therapeutics shows only a net buy transaction. It reports one open-market purchase of 5,000 shares by director Randy H. Thurman and no corresponding sales or dispositions in this specific insider filing.

What does the net-buy summary indicate in the Outlook Therapeutics (OTLK) Form 4?

The net-buy summary indicates that insiders covered by this Form 4 collectively bought 5,000 shares and sold none. For this filing, that reflects Randy H. Thurman’s single open-market purchase of 5,000 Outlook Therapeutics common shares at $0.429 each.